Post hoc exploratory analysis of two phase 2 trials of quizartinib monotherapy in patients (pts) with FLT3-ITD–mutated (mu) relapsed/refractory (R/R) AML with or without prior 1st-generation FLT3 tyrosine kinase inhibitors (TKI) treatment.

Mark J. Levis,Catherine C. Smith,Koji Ishizuka,Ken Kobayashi,Meena Arunachalam,Yibin Wang,Deborah Lazzaretto,Jorge E. Cortes

Post hoc exploratory analysis of two phase 2 trials of quizartinib monotherapy in patients (pts) with FLT3-ITD–mutated (mu) relapsed/refractory (R/R) AML with or without prior 1st-generation FLT3 tyrosine kinase inhibitors (TKI) treatment.

2018

Mark J. Levis
Catherine C. Smith
Koji Ishizuka
Ken Kobayashi
Meena Arunachalam
Yibin Wang
Deborah Lazzaretto
Jorge E. Cortes

7017Background: First-generation (1st gen) FLT3 TKIs such as sorafenib (SOR) / midostaurin (M) are increasingly used for treatment of FLT3-mu acute myeloid leukemia (AML). Quizartinib (Q) is a high...

Keywords:

Cancer research
Quizartinib
Tyrosine kinase
Physical therapy
Medicine
exploratory analysis
Midostaurin
Sorafenib
Oncology
in patient
post hoc
Internal medicine
Pathology
Myeloid leukemia

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations